A Open-label, Prospective, Phase 1b Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer

Trial Profile

A Open-label, Prospective, Phase 1b Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Rivoceranib (Primary) ; Carboplatin; Docetaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms LANCET
  • Most Recent Events

    • 03 Feb 2018 Planned number of patients changed from 60 to 40.
    • 03 Feb 2018 Planned primary completion date changed from 30 Aug 2019 to 30 Dec 2019.
    • 03 Feb 2018 Planned initiation date changed from 2 Jan 2018 to 2 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top